newwin
Luciann Nguyen
Settings
← Accounts
biotech

MedSIR

53
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

MedSIR

New trial — REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

New trialNCT06315010
53/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 2 trial NCT06315010 posted by MedSIR: "REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 195 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06315010
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
phase 2
—